Clinical efficiency of intra-cavity biotherapy patients with malignant effusions

Konstantin S. Titov; L. V Demidov; I. Zh Shubina; A. N Gritsay; A. V Egorova; M. V Kiselevsky

doi:10.17816/onco40102

Russian Journal of Oncology ›› 2015, Vol. 20 ›› Issue (2) : 8 -12. DOI: 10.17816/onco40102

Articles

research-article

Clinical efficiency of intra-cavity biotherapy patients with malignant effusions

Author information +

History +

PDF

Abstract

The study evaluatedfeasibility, safety and effectiveness of cell biotherapy based on allogenic LAK-cells in combination with recombinant interleukin-2 (IL-2) used for sistem antitumor immunotherapy. The clinical study involved cancer patients with metastatic effusions resistant to systemic chemotherapy. The results showed that intra-cavity immunotherapy was highly effective and well tolerated in treatment of patients with malignant effusions.

Keywords

immunotherapy / metastatic effusions / interleukin-2 / LAK-cells

Cite this article

Download citation ▾

Konstantin S. Titov, L. V Demidov, I. Zh Shubina, A. N Gritsay, A. V Egorova, M. V Kiselevsky. Clinical efficiency of intra-cavity biotherapy patients with malignant effusions. Russian Journal of Oncology, 2015, 20(2): 8-12 DOI:10.17816/onco40102

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Киселевский М.В. Адоптивная иммунотерапия при злокачественных опухолях. Вестник РАМН. 2003;1: 40-4.

[2]	Сельчук В.Ю., Бычков М.Б., Киселевский М.В. ред. Опухолевые серозиты. М.: Практическая медицина; 2011.

[3]	Титов К.С., Демидов Л.В, Шубина И.Ж., Киселевский М.В. Сравнение эффективности и переносимости внутрибрюшинной клеточной и ИЛ-2-иммунотерапии у больных с химиорезистентными асцитными формами рака желудка. Российский онкологический журнал. 2014; 3: 24-8.

[4]	Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G.H. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011; 137 (2): 305-10.

[5]	Manjili M.H. Revisiting cancer immunoediting by understanding cancer immune complexity. J. Pathol. 2011; 224 (1): 5-9.

[6]	Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J. Intern. Med. 2009; 266(2): 154-81.

[7]	Wang E., Panelli M.C., Monsurro V., Marincola F.M. A global approach to tumor immunology. Cell Mol. Immunol. 2004; 1 (4): 256-65.

[8]	Xue S.A., Stauss H.J. Enhancing immune responses for cancer therapy. Cell Mol. Immunol. 2007; 4 (3): 173-84.

[9]	June C.H. Adoptive T cell therapy for cancer in the clinic. J. Clin. Invest. 2007; 117 (6): 1466-76.

[10]

Rosenberg S.A., Lotze M.T., Yang J.C., Topalian S.L., Chang A.E., Schwartzentruber D.J. et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J. Natl. Cancer Inst. 1993; 85 (8): 622-32.

[11]	Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J. Cancer. 2011; 2: 363-8.

[12]	Liu X., Li D., Zhang C. et al. Treatment of 121 patients with malignant effusion due to advanced lung cancer by intrapleural transfer of autologous or allogeneic LAK cells combined with rIL-2. Chin. Med. Sci. J. 1993; 8 (3): 186-9.

[13]	Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A. et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002; 295: 2097-100.